Nikola (Nick) Gasic's questions to Vir Biotechnology Inc (VIR) leadership • Q1 2025
Question
Nikola (Nick) Gasic, on behalf of Roanna Ruiz, asked about VIR's expectations for the 24-week off-treatment data from the MARCH study in HBV, set to be presented at EASL. He also inquired about the potential implications of this data for partnership discussions.
Answer
Mark Eisner (Executive) noted that while he could not comment extensively ahead of the presentation, the company had previously signaled a target of a 20% functional cure rate for the doublet and 30% for the triplet. Marianne De Backer (Executive) added that any further development of the HBV program remains contingent on securing a worldwide development and commercialization partner.